TOPIC:

From the weekend:

hepatitiscnewdrugs.blogspot.com/2016/02/...hepatitis-c-bbc.html

hepatitiscnewdrugs.blogspot.com/2016/02/...ver-hepatitis-c.html

New Screening and treatment criteria from WHO:

hepatitiscnewdrugs.blogspot.com/2016/02/...-in-updated-who.html


Thousands recalled for hepatitis C test after NHS worker's diagnosis:
hepatitiscnewdrugs.blogspot.com/2016/02/...epatitis-c-test.html


Bristol-Myers Squibb (NYSE:BMY) Presents Data on All-Oral Hepatitis C Regimen:
hepatitiscnewdrugs.blogspot.com/2016/02/...ysebmy-presents.html

That last article is curious considering BMS withdrew application for approval of asuneprevir (in combination with daclatavir) in Oct 2014 Because -

In clinical trials, BMS’s combination, on the other hand, cured just 82 percent to 90 percent of those with genotype 1b after 24 weeks.

Source - www.hepmag.com/article/asunaprevir-end-26284-925493039

I wonder what changed, as they are reporting higher SVR rates in this trial?

Re Cirrhosis:
2/24/16

hepatitiscnewdrugs.blogspot.com/2016/02/...gy-therapeutics.html


Re Zepatier:

hepatitiscnewdrugs.blogspot.com/2016/02/...tier-vs-harvoni.html

sonix wrote: That last article is curious considering BMS withdrew application for approval of asuneprevir (in combination with daclatavir) in Oct 2014 Because -

In clinical trials, BMS’s combination, on the other hand, cured just 82 percent to 90 percent of those with genotype 1b after 24 weeks.

Source - www.hepmag.com/article/asunaprevir-end-26284-925493039

I wonder what changed, as they are reporting higher SVR rates in this trial?

Looks like the 2014 report relates to earlier trials for approval for use in US so probably consisted mostly of western patient profile whereas these latest late stage trial results are for an all Chinese patient profile. This differing result is possibly to be expected as various racial groupings show differing responses to the old interferon treatments and also susceptibility to fibrosis/cirrhosis.

Lots of good reading here:

Indian Patent Challenge:

hepatitiscnewdrugs.blogspot.com/2016/02/...enge-hearing-on.html

ABBVIE RECEIVES CHMP POSITIVE OPINION FOR VIEKIRAX® (OMBITASVIR/PARITAPREVIR/RITONAVIR TABLETS) + EXVIERA® (DASABUVIR TABLETS) WITHOUT RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C IN GENOTYPE 1B:

hepatitiscnewdrugs.blogspot.com/2016/02/...ositive-opinion.html

This version of the Guidance has been updated to reflect several important developments, including the recent approval of elbasvir/grazoprevir:

hepatitiscnewdrugs.blogspot.com/2016/02/...ir-hcv-guidance.html

Why Americans pay so much more for drugs:

hepatitiscnewdrugs.blogspot.com/2016/02/...-more-for-drugs.html


Quoted from the above article. Steve Miller, chief medical officer of Express Scripts wrote:

"The U.S. is 4.6 percent of the world's population, we're 32 percent of the world's drug revenue, and we're somewhere between 50 and 70 percent of world drug profitability," Miller said. "The United States has been spending money to protect the world for decades. We're now being asked to essentially fund all pharmaceutical drug development. ... We cannot continue to carry this burden."

Interesting...

hepatitiscnewdrugs.blogspot.com/2016/02/...000-pill-for-10.html

RE; Australia:

hepatitiscnewdrugs.blogspot.com/2016/02/...now-as-cheap-as.html

Lack of awareness, affordability, etc.

hepatitiscnewdrugs.blogspot.com/2016/02/...-affordable-but.html

Friday 3/4/2016

hepatitiscnewdrugs.blogspot.com/2016/03/...ugs-now-covered.html

hepatitiscnewdrugs.blogspot.com/2016/03/...-general-probes.html

The"Buyers' Club Era" article, among others:

hepatitiscnewdrugs.blogspot.com/2016/03/...s-with-news.html?m=1

Recommendations from John W. Ward, MD, director of the Division of Viral Hepatitis at the Centers for Disease Control and Prevention (CDC).:

hepatitiscnewdrugs.blogspot.com/2016/03/...re-out-of-reach.html

From the CDC:
Annual Report to the Nation: Cancer death rates continue to decline

Increase in liver cancer deaths cause for concern

hepatitiscnewdrugs.blogspot.com/2016/03/...ne-but-increase.html

Merck vs Gilead:
hepatitiscnewdrugs.blogspot.com/2016/03/...tis-c-drugs.html?m=1

Insurers rail against exorbitant drug costs:
hepatitiscnewdrugs.blogspot.com/2016/03/...t-high-cost.html?m=1

Some good reading here in "HCV Next"

hepatitiscnewdrugs.blogspot.com/2016/03/...g-gap-impact-of.html

3/18/16

hepatitiscnewdrugs.blogspot.com/2016/03/...-and-recruiting.html

Why U.S. prices will stay high:

hepatitiscnewdrugs.blogspot.com/2016/03/...ent-lowered.html?m=1